These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6526563)

  • 1. Nifedipine in scleroderma ulcerations.
    Woo TY; Wong RC; Campbell JP; Goldfarb MT; Voorhees JJ; Callen JP
    Int J Dermatol; 1984 Dec; 23(10):678-80. PubMed ID: 6526563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful combined medical and surgical treatment of a lower extremity sclerodermal ulcer.
    Grossman JA; Barrall DT; Dennison A; Lally EV
    Ann Plast Surg; 1988 Jun; 20(6):582-5. PubMed ID: 3133976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal cord stimulation utilization to treat the microcirculatory vascular insufficiency and ulcers associated with scleroderma: a case report and review of the literature.
    Provenzano DA; Nicholson L; Jarzabek G; Lutton E; Catalane DB; Mackin E
    Pain Med; 2011 Sep; 12(9):1331-5. PubMed ID: 21914119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic fibroblast growth factor treatment for skin ulcerations in scleroderma.
    Yamanaka K; Inaba T; Nomura E; Hurwitz D; Jones DA; Hakamada A; Isoda K; Kupper TS; Mizutani H
    Cutis; 2005 Dec; 76(6):373-6. PubMed ID: 16438426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
    Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Raynaud's phenomenon with ketanserin.
    Cox NH; Dufton PA
    Br Med J (Clin Res Ed); 1984 Oct; 289(6451):1078-9. PubMed ID: 6435782
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic leg ulceration as the presenting feature of diffuse systemic sclerosis in childhood.
    Wahezi DM; Ilowite NT; Kenney-Riley KM; Belamarich PF
    J Pediatr; 2011 Oct; 159(4):698. PubMed ID: 21784448
    [No Abstract]   [Full Text] [Related]  

  • 10. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
    Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M
    Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nifedipine in Raynaud's phenomenon associated with systemic sclerosis.
    Thakur SK; Gopinathan VP; Jagdish TK; Bhalla IP; Shetty KJ
    J Assoc Physicians India; 1986 Jul; 34(7):536. PubMed ID: 3759897
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of Bosentan in treatment of refractory sclerodermic bone prominences skin ulcers.
    Richetta AG; Mattozzi C; Maiani E; D'Epiro S; Cimillio M; Carboni V; Giancristoforo S; Calvieri S
    Clin Ter; 2008; 159(5):317-9. PubMed ID: 18998033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy].
    Becker H; Sunderkoetter C; Willeke P; Domschke W; Gaubitz M; Mohr M
    Z Rheumatol; 2009 Mar; 68(2):154-6. PubMed ID: 19156432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Capillaroscopic evaluation of the effects of nifedipine in patients with Raynaud's phenomenon].
    Riccio A; Pennarola R; Farinaro C; Scherillo G; Infranzi E; Del Puente A; Oriente P
    Clin Ter; 1988 May; 125(3):185-90. PubMed ID: 2973939
    [No Abstract]   [Full Text] [Related]  

  • 18. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifedipine as a therapeutic modality for Raynaud's phenomenon.
    Winston EL; Pariser KM; Miller KB; Salem DN; Creager MA
    Arthritis Rheum; 1983 Oct; 26(10):1177-80. PubMed ID: 6626276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-platelet effect of nifedipine in patients with systemic sclerosis.
    Rademaker M; Meyrick Thomas RH; Kirby JD; Kovacs IB
    Clin Exp Rheumatol; 1992; 10(1):57-62. PubMed ID: 1551280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.